Risk Factors of SARS-CoV-2 Infection in Cancer Patients Pre- and Post-vaccination

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Aug 9

PMID 35943973

Authors

Suliman A Alsagaby

Naif Khalaf Alharbi

Fahad A Alhumaydhi

Faisal Alsubaie

Mohammad Bosaeed

Abdulrhman Aljouie

Abdullah M Assiri

Kanan Alshammari

Affiliations

Soon will be listed here.

Abstract

Background: Severe complications from COVID-19 and poor responses to SARS-CoV-2 vaccination were commonly reported in cancer patients compared to those without cancer. Therefore, the identification of predisposing factors to SARS-CoV-2 infection in cancer patients would assist in the prevention of COVID-19 and improve vaccination strategies. The literature lacks reports on this topic from the Kingdom of Saudi Arabia (KSA). Therefore, we studied clinical and laboratory data of 139 cancer patients from King Abdulaziz Medical City, Riyadh, KSA.

Methods: The cancer patients fall into three categories; (i) uninfected with SARS-CoV-2 pre-vaccination and remained uninfected post-vaccination (control group; n = 114; 81%), (ii) pre-vaccination infected group (n = 16; 11%), or (iii) post-vaccination infected group (n = 9; 6%). Next, the clinical and lab data of the three groups of patients were investigated.

Results: Comorbidity factors like diabetes and hemodialysis were associated with the risk of infection in cancer patients before the vaccination (p<0.05). In contrast to breast cancer, papillary thyroid cancer was more prevalent in the infected patients pre- and post-vaccination (p<0.05). Pre-vaccination infected group had earlier cancer stages compared with the control group (p = 0.01). On the other hand, combined therapy was less commonly administrated to the infected groups versus the control group (p<0.05). Neutrophil to lymphocyte ratio was lower in the post-vaccination infected group compared to the control group (p = 0.01).

Conclusion: Collectively, this is the first study from KSA to report potential risk factors of SARS-CoV-2 infection in cancer patients pre- and post-vaccination. Further investigations on these risk factors in a larger cohort are worthwhile to draw a definitive conclusion about their roles in predisposing cancer patients to the infection.

References

Sheshah E, Sabico S, Albakr R, Sultan A, Alghamdi K, Al Madani K . Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia. Diabetes Res Clin Pract. 2020; 172:108538. PMC: 7661919. DOI: 10.1016/j.diabres.2020.108538. View

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

Rashedi J, Mahdavi Poor B, Asgharzadeh V, Pourostadi M, Kafil H, Vegari A . Risk Factors for COVID-19. Infez Med. 2020; 28(4):469-474. View

Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A . Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. J Natl Cancer Inst. 2021; 114(2):203-209. PMC: 8499747. DOI: 10.1093/jnci/djab174. View

Molinaro E, Leboeuf R, Shue B, Martorella A, Fleisher M, Larson S . Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid. 2009; 19(10):1035-41. DOI: 10.1089/thy.2008.0430. View

Smulever A, Abelleira E, Bueno F, Pitoia F . Thyroid cancer in the Era of COVID-19. Endocrine. 2020; 70(1):1-5. PMC: 7402074. DOI: 10.1007/s12020-020-02439-6. View

Fillmore N, La J, Szalat R, Tuck D, Nguyen V, Yildirim C . Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2020; 113(6):691-698. PMC: 7665587. DOI: 10.1093/jnci/djaa159. View

Gao Y, Ding M, Dong X, Zhang J, Azkur A, Azkur D . Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2020; 76(2):428-455. DOI: 10.1111/all.14657. View

Trimboli P, Camponovo C, Scappaticcio L, Bellastella G, Piccardo A, Rotondi M . Thyroid sequelae of COVID-19: a systematic review of reviews. Rev Endocr Metab Disord. 2021; 22(2):485-491. PMC: 8038866. DOI: 10.1007/s11154-021-09653-1. View

10.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

11.

Alshaikh M, Alotair H, Alnajjar F, Sharaf H, Alhafi B, Alashgar L . Cardiovascular Risk Factors Among Patients Infected with COVID-19 in Saudi Arabia. Vasc Health Risk Manag. 2021; 17:161-168. PMC: 8071203. DOI: 10.2147/VHRM.S300635. View

12.

Shabrawishi M, Al-Gethamy M, Naser A, Ghazawi M, Alsharif G, Obaid E . Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. PLoS One. 2020; 15(8):e0237130. PMC: 7410246. DOI: 10.1371/journal.pone.0237130. View

13.

Bornstein S, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A . Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8(6):546-550. PMC: 7180013. DOI: 10.1016/S2213-8587(20)30152-2. View

14.

Stampfer S, Goldwater M, Jew S, Bujarski S, Regidor B, Daniely D . Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021; 35(12):3534-3541. PMC: 8320411. DOI: 10.1038/s41375-021-01354-7. View

15.

Berger J, Wohlfarth P, Konigsbrugge O, Knaus H, Porpaczy E, Kaufmann H . SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria : Findings of a multicentric nationwide study. Wien Klin Wochenschr. 2022; 134(9-10):371-376. PMC: 8852912. DOI: 10.1007/s00508-022-02006-1. View

16.

Alguwaihes A, Al-Sofiani M, Megdad M, Albader S, Alsari M, Alelayan A . Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study. Cardiovasc Diabetol. 2020; 19(1):205. PMC: 7718833. DOI: 10.1186/s12933-020-01184-4. View

17.

Al-Quteimat O, Amer A . The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol. 2020; 43(6):452-455. PMC: 7188063. DOI: 10.1097/COC.0000000000000712. View

18.

Kuderer N, Choueiri T, Shah D, Shyr Y, Rubinstein S, Rivera D . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241):1907-1918. PMC: 7255743. DOI: 10.1016/S0140-6736(20)31187-9. View

19.

Gupta R, Ghosh A, Singh A, Misra A . Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020; 14(3):211-212. PMC: 7102582. DOI: 10.1016/j.dsx.2020.03.002. View

20.

Andrew T, Alrawi M, Lovat P . Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic. Clin Exp Dermatol. 2020; 46(1):145-146. PMC: 7436874. DOI: 10.1111/ced.14411. View